NCT06433869View on ClinicalTrials.gov

The Efficacy of Bevacizumab and Serplulimab Combined With Recombinant Mutant HumanTumor Necrosis Factor(rmhTNF-NC) in the Treatment of Malignant Ascites

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

December 14, 2023

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Malignant Ascites
Interventions
DRUG

serplulimab

Additional intraperitoneal injection of bevacizumab or rmhTNF-NC is added to the PD-1 inhibitor.

DRUG

Bevacizumab

Intraperitoneal injection of bevacizumab is added to PD-1 inhibitor or rmhTNF-NC.

DRUG

rmhTNF-NC

Intraperitoneal injection of rmhTNF-NC is added to PD-1 inhibitor or bevacizumab.

Trial Locations (3)

510060

RECRUITING

Cancer center of SunYat-sen University, Guangzhou

Unknown

RECRUITING

Zhang Dongsheng, Guangzhou

RECRUITING

Zhang Dongsheng, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER